ClinicalTrials.gg
CompletedNCT05995704Updated Oct 24, 2024

Evaluation of Apraglutide on Gastric Emptying

A Phase 1 interventional study of Apraglutide and Placebo in Healthy Subjects, sponsored by VectivBio AG. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-24.

Sponsored by VectivBio AG (part of Ironwood Pharmaceuticals, Inc.) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jul 2023, 3 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The primary objective is to assess the effect of apraglutide on gastric emptying of liquids in healthy subjects, as measured by the PK of acetaminophen mixed with a liquid meal.

Read the detailed description

This is a single-center, double-blind, randomized, multiple-dose, parallel trial with a total duration of up to 50 days. The trial population will consist of healthy volunteers. Eligible subjects will be randomized to receive either subcutaneous (SC) apraglutide or matching placebo. The effect of apraglutide on gastric emptying of liquids will be assessed by the measure of PK of acetaminophen mixed with a liquid meal.

There will be two treatment periods, occurring according to the same sequence. In Period 1 acetaminophen will be given on Day 1, apraglutide/placebo will be injected on Day2. In Period 2 apraglutide/placebo will be injected on Day 9 and acetaminophen will be given on Day 10. This will allow to assess the PK of acetaminophen without the effect of apraglutide in Period 1, and to assess the PK of acetaminophen at the maximum concentration of apraglutide in Period 2.

02

Conditions studied

  • Healthy Subjects

Keywords

  • Gastric emptying
  • Pharmacokinetics of acetaminophen
03

In context

Lead sponsor

VectivBio AG is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.

First submitted before VectivBio AG became part of Ironwood Pharmaceuticals, Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 45 years inclusive
  • Subjects who are willing and able to comply with the study procedures
  • Subjects able to understand and willing to sign the
  • (BMI) of ≥18.0 to ≤30.0 kg/m2; and a total body weight of >50 kg (110 lb).
  • Women of (WOCBP) having undergone bilateral tubal occlusion or with vasectomized partner. Sterilized or infertile or females.
  • Male subjects with a WOCBP partner using highly effective methods of and agreeing on no sperm donation during the trial and for 2 weeks after (EOT) visit.

Exclusion criteria

Exclusion Criteria:

  • History of GI, bronchopulmonary, neurological, cardiovascular, endocrine, or allergic disease
  • Known to the medicinal product (IMP), any of their or drugs of the same class
  • If capable of reproduction, unwilling to use an effective form of
  • If a , a positive urine/blood pregnancy test
  • Breast-feeding women
  • Positive urine/blood test for alcohol and drugs of abuse
  • Use of prohibited medications or herbal remedies
  • Known presence or history of intestinal polyps
  • Known presence or history of any type of cancer
  • Pancreatic events such as acute pancreatitis, pancreatic duct stenosis, pancreas infection, and increased blood amylase and lipase (>2.0-5.0×)
  • Participation in an investigational drug or device study within 30 days prior to Screening
  • Donation of blood over 500 mL within 2 months prior to Screening
  • Use of tobacco products (i.e., smokes more than 5 cigarettes per day or equivalent)
  • Concomitant disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this trial
  • Any intercurrent clinically significant illness in the previous 28 days before Day 1 of this study
  • Positive blood screen for (HIV) antigen/antibody combo, hepatitis A (HAV IGM), surface antigen (HBsAgB), or virus (HCV)
  • Unwillingness or inability to comply with the study protocol for any other reason
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Apraglutide SC injections

    Drug: Apraglutide · Drug: Acetaminophen

  • Placebo comparator
    Placebo

    Drug: Placebo · Drug: Acetaminophen

Interventions

  • Peptide analogue of GLP-2

  • DrugPlacebo

    Matching placebo to apraglutide

  • Acetaminophen mixed with a liquid meal

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration (Cmax) of acetaminophen

    Time frame: 0-300 Minutes

  2. Time at which the maximum plasma concentration is observed (tmax) of acetaminophen

    Time frame: 0-300 Minutes

  3. Area under the acetaminophen concentration-time curve: AUCinf (AUClast in case AUCinf cannot be estimated)

    Time frame: 0-14 hours

  4. Area under the acetaminophen concentration-time curve: AUC0-300min

    Time frame: 0-300 Minutes

  5. Area under the acetaminophen concentration-time curve: AUC0-60min

    Time frame: 0-60 Minutes

Secondary outcomes

  1. Height

    In cm

    Time frame: Through study completion, up to 24 days

  2. Weight

    In kg

    Time frame: Through study completion, up to 24 days

  3. Physical examination

    Clinically significant outcome (as normal or abnormal) for physical examination of eyes, neurological, gastrointestinal, respiratory, circulatory, muscular, cardiovascular, lymphatic, ears, nose, throat.

    Time frame: Through study completion, up to 24 days

  4. The incidence, nature and severity of adverse events (AEs) with apraglutide

    Time frame: Through study completion, up to 24 days

  5. Clinical chemistry

    Clinical Chemistry panel of analytes will be examined for clinically significant changes. Clinical chemistry analytes will be listed by subject. Descriptive statistics will be used to assess any changes in clinical laboratory results during and following trial treatment administration. Values outside the reference ranges will be highlighted and clinical significance stated.

    Time frame: Through study completion, up to 24 days

  6. Hematology

    Hematology panel of analytes will be examined for clinically significant changes. Hematology analytes will be listed by subject. Descriptive statistics will be used to assess any changes in clinical laboratory results during and following trial treatment administration. Values outside the reference ranges will be highlighted and clinical significance stated.

    Time frame: Through study completion, up to 24 days

  7. Hemostasis

    Hemostasis INR will be examined for clinically significant changes

    Time frame: Through study completion, up to 24 days

  8. Anti-drug antibodies (ADA) analysis

    ADA will be will be examined for clinically significant changes

    Time frame: Through study completion, up to 24 days

  9. Urine analysis

    Urine analysis panel of analytes will be examined for clinically significant changes

    Time frame: Through study completion, up to 24 days

  10. Occurrence of clinically relevant changes in vital signs

    Systolic and diastolic blood pressure in mmHg

    Time frame: Through study completion, up to 24 days

  11. Occurrence of clinically relevant changes in vital signs

    Pulse rate in Beats per Minute

    Time frame: Through study completion, up to 24 days

  12. Changes in body temperature in °C

    Time frame: Through study completion, up to 24 days

  13. Occurrence of clinically relevant changes in electrocardiogram

    ECG QT Interval

    Time frame: Through study completion, up to 24 days

  14. Occurrence of clinically relevant changes in electrocardiogram

    ECG PR interval

    Time frame: Through study completion, up to 24 days

  15. Occurrence of clinically relevant changes in electrocardiogram

    ECG QRS interval

    Time frame: Through study completion, up to 24 days

  16. Occurrence of clinically relevant changes in electrocardiogram

    ECG rhythm

    Time frame: Through study completion, up to 24 days

07

Study locations

1 site
  • ICON Clinical Research Unit
    Groningen, Netherlands
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Jul 2023, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2023
First posted
Aug 16, 2023
StartActual
Mar 2, 2023
Primary completionActual
Jul 24, 2023
CompletionActual
Jul 24, 2023
Last update
Oct 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05995704
Lead sponsor
VectivBio AG
Responsible party
Sponsor
First posted
Aug 16, 2023
Start date
Mar 2, 2023
Primary completion
Jul 24, 2023
Completion
Jul 24, 2023
Last update
Oct 24, 2024

Study contacts

Tomasz Masior
study director · VectivBio AG

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apraglutide

Start the discussion